In short
Clinical trials are studying Mercaptamine-Pantetheine Disulfide Acetate in patients with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). These studies aim to assess safety, tolerability, and efficacy in people with this rare condition. The available trial data describe a randomized Phase 2 study in adults with MELAS.
Key points
- Clinical trial data for Mercaptamine-Pantetheine Disulfide Acetate describe one Phase 2 study in people with MELAS, a rare mitochondrial disease. The study was randomized, double-blind, and placebo-controlled, which means treatment assignment was done by chance and neither patients nor staff knew who received the study drug. The trial enrolled 12 participants and was completed. The main outcome was change in functional capacity measured by the 12-minute walking test over 24 weeks. Safety was also measured using adverse events, lab tests, physical exams, vital signs, ECG results, and seizure activity.
Trial overview
The available data describe one interventional study of Mercaptamine-Pantetheine Disulfide Acetate listed as oral TTI-0102 in the trial record. It studied patients with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), a rare condition that affects energy-making parts of cells and can cause brain and muscle problems.
The study was Phase 2, which means it was an early clinical research stage focused on signs of benefit and continued safety testing in a small group of people. The trial status was completed, and it enrolled 12 participants.
Study design and treatment groups
This study was randomized, so people were assigned to a study group by chance rather than by choice. It was also double-blind and placebo-controlled, meaning neither the participants nor the study team knew who received the study treatment and who received the placebo, which is a look-alike treatment with no active drug.
The title says the study aimed to assess the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of oral TTI-0102 compared with placebo for up to 6 months in patients with MELAS. In simple terms, the researchers wanted to see whether the treatment may help, whether it was acceptable to take, and how the body handled it and responded to it.
The intervention list includes oral TTI-0102 and Pearlitol® 100 SD (mannitol), which was used as the placebo comparator in the source data.
Who could participate
The trial targeted patients with MELAS. The source data do not provide more detailed entry rules such as age limits, disease severity, or other medical requirements.
Because the study was small, only a limited number of people could take part. This kind of study is often used to learn more about a treatment in a carefully selected group before larger trials are done.
What was measured
The main outcome was change in functional capacity, measured with the 12-minute walking test (12-MWT) from Day 1 or baseline to Week 24 or study exit. Functional capacity means how well a person can do physical tasks in daily life, and the walking test is a simple way to measure that ability.
Safety and tolerability were also measured. The study tracked the number, severity, and relationship of adverse events, which are unwanted health problems that happen during a trial, whether or not they are caused by the study treatment.
Other safety checks included changes in laboratory tests, physical exam findings, vital signs, 12-lead electrocardiography, and seizure activity. A 12-lead ECG is a heart tracing test, and seizure activity refers to episodes of abnormal electrical activity in the brain.
Why this trial matters
This trial focuses on a rare disease with serious symptoms, so even a small study can help researchers learn whether a treatment deserves further study. The design used a placebo comparison and blinded assignment, which helps make the results more reliable.
Because the study measured both walking ability and safety markers, it looked at whether the treatment might help patients function better while also checking for harm. The completed Phase 2 design shows that the trial was meant to give early answers about possible benefit in people with MELAS.